Liquidia (LQDA) vs Maravai LifeSciences (MRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Liquidia (LQDA) over the past year, gaining 116.5% versus a gain of 16.4%. Over five years, LQDA leads with a +775.6% price change compared with -80.6% for MRVI. Maravai LifeSciences is the larger company by market cap ($2.67 billion vs $2.51 billion), about 1.1 times the size, while Liquidia is growing revenue faster (+1031.2% vs -28.3%).
Liquidia converts more of its revenue into profit, with a net margin of -43.5% versus -70.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LQDA | MRVI |
|---|---|---|
| Share price | $28.02 | $7.21 |
| Market cap | $2.51B | $2.67B |
| 1-day change | +5.02% | -2.96% |
| YTD return | -18.76% | +121.85% |
| 1-year return | +16.36% | +116.52% |
| 5-year return | +775.63% | -80.56% |
| P/E ratio (TTM) | 20.16 | — |
| Forward P/E | 11.66 | — |
| EPS (TTM) | $1.39 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $158.32M | $185.74M |
| Revenue growth (YoY) | +1031.18% | -28.34% |
| Net income (latest FY) | $-68.92M | $-130.77M |
| Gross margin | — | 18.30% |
| Operating margin | -32.45% | -115.89% |
| Net margin | -43.53% | -70.41% |
| 52-week high | $93.61 | $9.42 |
| 52-week low | $21.94 | $2.55 |
| Distance from 52-week high | -70.07% | -23.46% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +77.27% | +8.60% |
| Average volume | 2.40M | 3.36M |
| Shares outstanding | 89.51M | 148.99M |
| Employees | 216 | 415 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed LQDA by 100.2 percentage points over the past year.
- Liquidia is more profitable, keeping -43.5 cents of every revenue dollar as net income versus -70.4 cents for Maravai LifeSciences.
- Liquidia grew revenue faster in its latest fiscal year (+1031.18% vs -28.34%).
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
LQDA vs MRVI FAQ
Which is bigger, Liquidia or Maravai LifeSciences?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $2.67B compared with $2.51B for Liquidia (LQDA).
Which stock has performed better over the past year, LQDA or MRVI?
MRVI returned +116.52% over the past 12 months, compared with +16.36% for LQDA (price return, excluding dividends). Past performance does not predict future results.
Are Liquidia and Maravai LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.